Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Allergan

About a dozen advocacy groups and unions, including Public Citizen and the American Federation of Teachers, wrote the Federal Trade Commission on Thursday urging it to consider blocking drugmaker AbbVie Inc's planned $63 billion purchase of Botox maker Allergan Plc.

Consumer groups, unions urge caution on $63 billion AbbVie deal for Allergan

Revenue from AbbVie's inflammation treatment Humira will crash to $3 billion annually by 2025, an analyst said Thursday — but he upgraded AbbVie stock ahead of its Allergan buyout.
The post Humira Sales Will Crash To $3 Billion — Why AbbVie Stock Got An Upgrade appeared first on Investor's Business Daily.

Humira Sales Will Crash To $3 Billion — Why AbbVie Stock Got An Upgrade

Bristol-Myers

Eli Lilly

Merck

Pfizer

Teva Pharmaceutical

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials.

Short Sellers Can’t Make Up Their Minds on Big Pharma

The situation for AbbVie probably isn't nearly as bad as you think it is.

Anxious About AbbVie? Here Are 4 Things You Should Know

Alexion Pharma

Bausch Health Companies Inc

Cigna

CVS Health

Intercept Pharma

Johnson & Johnson

PRA Health Sciences

Eli Lilly, Alexion and AbbVie are just some of the top healthcare stocks to buy here, now that disappointing news has driven them to cheap prices.

10 Healthcare Stocks to Buy Despite the Headlines

AbbVie's stock price only knew one direction for almost two years as a failed multi-billion dollar acquisition, an announced $63B acquisition and the end-of-life for HUMIRA have been fueling pessimism.

AbbVie: The 6.5% Yield Window Won't Stay Open Much Longer

Caterpillar

Federal Realty Investment Trust

Altria

Walgreens

Exxon Mobil

Investor concerns about a potential recession and bear market are at the highest levels in a decade. The media is constantly hyping the idea that a recession is imminent.

The 7 Best Dividend Aristocrats To Buy With Recession Risk This High

Enterprise Products Partners

Iron Mountain

These stocks provide dependable high-dividend yields along with solid growth prospects.

3 Stocks to Buy With Dividends Yielding More Than 6%.

EXTON, Pa., Sept.  04, 2019  (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) announced today that they have entered into an immuno-oncology clinical research collaboration with AbbVie, a global, research-based biopharmaceutical company.  The purpose of the collaboration is to conduct a clinical study evaluating whether combinations of an OX40 agonist (ABBV-368), a TLR-9 agonist (tilsotolimod), chemotherapy (nab-paclitaxel) and/or an anti-programmed cell death 1 (PD-1) antagonist (ABBV-181) stimulate the immune system resulting in anti-tumor responses.

Idera Pharmaceuticals Announces Immuno-Oncology Clinical Research Collaboration with AbbVie

AbbVie failed big-time with its decision to buy Stemcentrx to get Rova-T. Here's what investors can learn from its mistake.

3 Lessons From AbbVie's $5.8 Billion Blunder With Cancer Drug Rova-T

Gilead Sciences

AT&T

Low valuations, high prices: These three stocks appear to be ready to put in your shopping cart right now.

3 High-Yield Dividend Stocks to Buy on Sale

IDMC recommends termination of AbbVie's (ABBV) late-stage study on its small cell lung cancer candidate, Rova-T. AbbVie discontinues development.

AbbVie Ends Rova-T Program as 3rd Lung Cancer Study Fails

Shares of AbbVie Inc. ABBV, +0.61% rose 1.5% in premarket trade Thursday after the company announced it had shut down its troubled Rova-T research and development program.

AbbVie is shutting down its troubled Rova-T R&D program

Merger arbitrage can generate above-market returns in a short time for those willing to bear the risk of the merger not closing. While over 80% of deals eventually close, the downside can be significant for the ones that don't.

AbbVie Shareholders Can Earn 17% On Excess Cash Through Merger Arbitrage

AbbVie Inc. offers investors a dividend yield above 6%, but how secure are it's dividends?

Should You Buy AbbVie for the Dividend?

Ford Motor Company

Occidental Petroleum

Schlumberger

Even though interest rates have plunged back to the levels seen six and seven years ago, the reality is that we are in some of the lowest rate levels in over a generation.

5 Incredible Blue Chip Stocks With 6% or Higher Dividends

AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock?

AbbVie (ABBV) Down 1% Since Last Earnings Report: Can It Rebound?

Which stock wins in a battle between these two big pharma companies?

Better Buy:  Johnson & Johnson vs. AbbVie

AbbVie's stock currently sells for a P/E of 8x and sports a 6.4% yield.

AbbVie: Low P/E Multiple, Solid Dividend And Favorable Growth

The FDA just gave a thumbs-up to rheumatoid arthritis drug Rinvoq. It could become AbbVie's biggest immunology blockbuster after Humira.

AbbVie's Latest FDA Approval Is Its Most Important Immunology Win Since Humira

Archer-Daniels-Midland Company

Citizens Financial Group

Kohl's

Seagate Technology Holdings PLC

U.S. high-dividend stocks are trading at their biggest discount in four decades as investors flock to bonds, pushing down their yields.

High-Dividend Stocks on Historic Discount as Yields Plunge, says Goldman

AbbVie's (ABBV) oral JAK inhibitor, upadacitinib, receives FDA approval for treating rheumatoid arthritis under the trade name of Rinvoq. Shares up.

AbbVie's JAK Inhibitor Rinvoq Receives FDA Approval for RA

Novartis

FDA approvals for these drugs could translate to billions of dollars for a few companies.

5 Biggest New Drug Approvals Potentially on the Way in 2019

AbbVie received FDA approval for Upadacitinib to treat patients with rheumatoid arthritis who don't respond to or can't tolerate treatment with methotrexate.

AbbVie's FDA Approval For RINVOQ Sets Up First Phase Of Deployment Plan To Counter Humira Issue

Shares of AbbVie leapt higher Friday after the Food and Drug Administration approved its new rheumatoid arthritis treatment — a potential rival to drugs from Eli Lilly and Pfizer.
The post How AbbVie Plans To Take On Pfizer, Lilly — And Kick Its Humira Habit appeared first on Investor's Business Daily.

News for AbbVie Stock (ABBV)